Dr. Jeffrey Etemad

Pricing Guide for Dr. Etemad’s Intellxx Panels:

Initial Intellxx testing package:
Intellxx testing, order kit through Intellxx, 15 minute phone consultation, then one hour to review results via telehealth.

Cost: $500 plus cost of testing (can add in person one hour visit within 12 months of consultation for Osteopathic treatment for $400).

This will cover Intellxx testing for any of the following combination packages that involve:
Executive ($1200), Resilient Brain ($1300). The Powerhouse ($1700), which includes all three standard panels, requires a 90 minute consultation and costs $750.

Single standard panel package:
Intellxx testing, order kit through Intellxx, 15 minute phone consultation, then 45 minute telehealth consultation to review results
Cost: $400 plus cost of testing (can add in person one hour visit within 12 months of consultation for Osteopathic treatment for $400). This will cover Intellxx testing for any of the following panels.

Medical Overview ($700), Brain Optimization ($900), and Mental Wellness ($900), Neurodevelopmental panel ($1150)
New lower cost package for new panel:
Intellxx new testing panel, Spotlight on Anxiety and Depression ($450), 15 minute phone consultation plus 30 minute telehealth results review.
Cost: $200 (can add in person one hour visit within 12 months of consultation for Osteopathic treatment for $400)

A lot of people ask me why someone would choose Intellxx over a direct to consumer genomics test such as 23 and Me. Here is some information put together by Intellxx on their website:

A lot of people ask me why someone would choose Intellxx over a direct to consumer genomics test such as 23 and Me. Here is some information put together by Intellxx on their website:

Discussion of IntellxxDNA™ vs. Direct to Consumer Genomic Testing Numerous things are wonderful and even wondrous when looking at a genomic companies' offerings. And certainly, they each play to their strength -- as they should. But let’s explore some of the differences between Direct to Consumer (DTC) tests and the IntellxxDNA™ Clinical Decision Support Tool. (CDS) Let’s first recognize that genomic data is not the same across different companies regardless of whether they are DTC or Direct to Health Care Providers (HCP). Here are some important things to know. 1. Content: Each company chooses, on what genomic information they would like to focus. The focus of IntellxxDNA™ is actionable, clinically relevant genetic variants. Specifically, we focus on improving outcomes, preventing chronic illnesses and optimizing brain health. 2. Clinical Relevance: Whether or not the genomic information presented by a tool is clinically relevant is an important and distinguishing factor that must be considered when deciding to use a specific test. But even more importantly, along with that clinically relevant information, what does the test offer in terms of potential modifications? In other words, is it actionable? What will you as a clinician do with the results? 3. Reproducibility: The various technologies used both to harvest and more importantly, to analyze genomic data have varying benefits, as well as varying levels of reproducibility and reliability. At IntellxxDNA™ we have contracted with a CLIA/CAP certified lab that uses a variety of techniques to obtain accurate patient genotype information. Downloading large amounts of raw data from a direct to consumer test designed primarily for ancestry information and “edutainment” is not appropriate for medical decision making. Having worked with a validation lab, we can tell you with confidence that some of the downloadable SNPs in the raw data have accuracy of less than 50%.

There are important variants such as Apo E2 that validate at less than 75% accuracy and that is why the 23andMe health report does not report on many variants. You will note the boxed warning on the 23andMe raw data page: “The raw data provided by 23andMe has undergone a general quality review however only a subset of markers has been individually validated for accuracy. The data from 23andMe’s Browse Raw Data feature is suitable only for informational use and not for medical, diagnostic or other use. Consult with a healthcare professional before making any major lifestyle changes.” 4. Chronic Diseases are Multifactorial: Many DTC companies look at genes or SNPs independently rather than in combination. This action limits the information that can be provided about a particular disease state, what the SNPs mean clinically and what can be done. IntellxxDNA™ reports on panels of interpreted key contributing SNPs and key SNPs that relay benefit. This provides a more complete picture for discussion and can be reassuring to a patient that their “genes are not all bad”. 5. Robust Number of SNPs Evaluated in Each Panel: Some companies will report on a health risk by identifying only two SNPs in a disease pathway. For example, in a well-known DTC health report test reporting on Parkinson’s, if the patient has 0 SNPs in their Parkinson’s profile, the patient might assume that they will not get Parkinson’s. However, this test is choosing to look at only 2 SNPs when there are more than 100 SNPs that have been associated with Parkinson’s Disease risk and the 2 they present only explains about 5% or less of Parkinson’s. In essence, it is impossible to compare a DTC test or any other genomic companies to another as they are all different from each other! DTC testing helped to launch the field of genomics and has been an amazing tool for connecting individuals to their ancestry across the world and giving some basic awareness regarding the role of genomics in health and wellness. IntellxxDNA™ is the only clinical decision support tool developed by and for integrative and functional medicine practices. For patients looking to optimize brain function, optimize their overall health and prevent chronic diseases such as heart disease, diabetes, osteoporosis, obesity, etc. IntellxxDNA™ is the tool of choice; providing accurate, clinically relevant and actionable genomic information